Article
The combination of TRAIL and the Smac mimetic LCL-161 induces an irreversible phenotypic change of MCF-7 breast cancer cells.
Experimental and molecular pathology - 1 Apr 2022
Granqvist Victoria, Holmgren Christian, Larsson Christer
Abstract excerpt
INTRODUCTION: Breast cancer is the most common malignancy affecting women. Although the prognosis generally is good, a substantial number of patients still suffer from relapse, emphasizing the need for novel treatments. Smac mimetics were developed to facilitate cell death by blocking inhibitor of apoptosis proteins (IAPs). It has been suggested that TNF-related apoptosis inducing ligand (TRAIL) can be used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
